Corvus Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
CRVS$11.37+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Change in Stockholders’ Equity
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, except share data)
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Nine Months Ended September 30, 2024 | |||||||||||||||||
| · · · · · · · Accumulated · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-in · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · Shares · Amount · Capital · Income · Deficit · Equity | |||||||||||||||||
| Balance at December 31, 2023 | | 49,038,582 | | $5 | | $374,363 | | $(967) | | $(334,717) | | $38,684 | |||||
| Stock-based compensation expense | | — | | | — | | | 689 | | | — | | | — | | | 689 |
| Unrealized loss on marketable securities | | — | | | — | | | — | | | (15) | | | — | | | (15) |
| Foreign currency translation adjustment | | — | | | — | | | — | | | (293) | | | — | | | (293) |
| Net loss | | — | | | — | | | — | | | — | | | (5,701) | | | (5,701) |
| Balance at March 31, 2024 | | 49,038,582 | | $5 | | $375,052 | | $(1,275) | | $(340,418) | | $33,364 | |||||
| Common stock issued in connection with registered direct offering, net | | 13,512,699 | | | 1 | | | 16,404 | | | — | | | — | | | 16,405 |
| Pre-funded warrants issued in connection with registered direct offering, net | | — | | | — | | | 5,031 | | | — | | | — | | | 5,031 |
| Stock-based compensation expense | | — | | | — | | | 768 | | | — | | | — | | | 768 |
| Unrealized loss on marketable securities | | — | | | — | | | — | | | 5 | | | — | | | 5 |
| Foreign currency translation adjustment | | — | | | — | | | — | | | (85) | | | — | | | (85) |
| Net loss | | — | | | — | | | — | | | — | | | (4,262) | | | (4,262) |
| Balance at June 30, 2024 | | 62,551,281 | | $6 | | $397,255 | | $(1,355) | | $(344,680) | | $51,226 | |||||
| Common stock issued on exercise of stock options | | 28,750 | | | — | | | 50 | | | — | | | — | | | 50 |
| Stock-based compensation expense | | — | | | — | | | 733 | | | — | | | — | | | 733 |
| Unrealized gain on marketable securities | | — | | | — | | | — | | | 152 | | | — | | | 152 |
| Foreign currency translation adjustment | | — | | | — | | | — | | | 465 | | | — | | | 465 |
| Net loss | | — | | | — | | | — | | | — | | | (40,217) | | | (40,217) |
| Balance at September 30, 2024 | | 62,580,031 | | $6 | | $398,038 | | $(738) | | $(384,897) | | $12,409 | |||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Nine Months Ended September 30, 2023 | |||||||||||||||||
| · · · · · · · Accumulated · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · Total | |||||||||||||||||
| · · Common Stock · · Paid-in · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · Shares · Amount · Capital · Income · Deficit · Equity | |||||||||||||||||
| Balance at December 31, 2022 | | 46,553,511 | | $5 | | $364,361 | | $(563) | | $(307,688) | | $56,115 | |||||
| Common stock issued on exercise of stock options | | 15,000 | | | — | | | 4 | | | — | | | — | | | 4 |
| Stock-based compensation expense | | — | | | — | | | 492 | | | — | | | — | | | 492 |
| Unrealized gain on marketable securities | | — | | | — | | | — | | | 41 | | | — | | | 41 |
| Foreign currency translation adjustment | | — | | | — | | | — | | | 88 | | | — | | | 88 |
| Net loss | | — | | | — | | | — | | | — | | | (7,873) | | | (7,873) |
| Balance at March 31, 2023 | | 46,568,511 | | $5 | | $364,857 | | $(434) | | $(315,561) | | $48,867 | |||||
| Stock-based compensation expense | | — | | | — | | | 537 | | | — | | | — | | | 537 |
| Unrealized loss on marketable securities | | — | | | — | | | — | | | (1) | | | — | | | (1) |
| Foreign currency translation adjustment | | — | | | — | | | — | | | (933) | | | — | | | (933) |
| Issuance of common stock in connection with at-the-market offering, net | | 2,329,851 | | | — | | | 7,516 | | | — | | | — | | | 7,516 |
| Net loss | | — | | | — | | | — | | | — | | | (6,503) | | | (6,503) |
| Balance at June 30, 2023 | | 48,898,362 | | $5 | | $372,910 | | $(1,368) | | $(322,064) | | $49,483 | |||||
| Common stock issued on exercise of stock options | | 8,168 | | | — | | | 8 | | | — | | | — | | | 8 |
| Stock-based compensation expense | | — | | | — | | | 546 | | | — | | | — | | | 546 |
| Unrealized gain on marketable securities | | — | | | — | | | — | | | 5 | | | — | | | 5 |
| Foreign currency translation adjustment | | — | | | — | | | — | | | (80) | | | — | | | (80) |
| Issuance of common stock in connection with at-the-market offering, net | | 132,052 | | | — | | | 327 | | | — | | | — | | | 327 |
| Net loss | | — | | | — | | | — | | | — | | | (6,000) | | | (6,000) |
| Balance at September 30, 2023 | | 49,038,582 | | $5 | | $373,791 | | $(1,443) | | $(328,064) | | $44,289 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.